External Beam Radiation Therapy Market

USD 7.4 billion in 2026 to USD 13.9 billion by 2036 at a 6.5% CAGR.

• As per Fact.MR analysis, the external beam radiation therapy market crossed a valuation of USD 6.95 billion in 2025.
• Demand will grow from USD 7.4 billion in 2026 to USD 13.9 billion by 2036.
• The forecast records a 6.5% CAGR from 2026 to 2036 as healthcare providers invest in advanced radiation therapy technologies and cancer treatment capabilities.

Source: Fact.MR analysis. Updated Oct 29, 2026

What are the defining numbers behind External Beam Radiation Therapy Market growth?

USD 6.5 billion absolute opportunity between 2026 and 2036.

• Demand Drivers in the Market
  • Investment in modern radiotherapy equipment has driven the market growth. In May 2026, India's Ministry of Defence reported the commissioning of a ring-gantry linear accelerator at Army Hospital (Research & Referral), Delhi. The system supports techniques including intensity-modulated radiation therapy, image-guided radiation therapy, stereotactic body radiation therapy, and stereotactic radiosurgery [2].
  • Government-funded cancer care programs and expanded access to radiotherapy services support growth in the External Beam Radiation Therapy Market by helping more patients access advanced radiation treatment. Brazil's Ministry of Health reported in October 2026 that new linear accelerators were being installed under national health programmes. The announcement covered equipment in Santos and the expansion of radiotherapy availability in Roraima, illustrating efforts to address regional access gaps [3].
  • Faster treatment delivery and adaptive workflows drive the growth of the External Beam Radiation Therapy Market by improving treatment efficiency and enabling clinicians to adjust radiation plans according to changes in tumor position or patient anatomy. Siemens Healthineers announced the Accela radiotherapy solution in September 2026, while Elekta announced expanded adaptive radiotherapy capabilities during the same month. These developments highlight industry efforts to improve treatment speed, precision, and workflow efficiency [4] [5].  
• Key Segments Analyzed
  • By Product Type: Linear Accelerators are projected to lead with 42.3% in 2026, reflecting their established role in delivering external radiation therapy across a broad range of cancer indications.
  • By Application: Prostate Cancer will account for 24.5% of the market in 2026. Radiation treatment planning depends on disease stage, tumor characteristics, and the patient's wider clinical needs.
  • By End-User: Hospitals hold prominent share of 52.7% in 2026, supported by their role in coordinating radiation oncology with imaging, surgery, medical oncology, and inpatient or outpatient care.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, states, “External beam radiation therapy providers are likely to place greater emphasis on treatment precision, workflow efficiency, and equipment utilization. Manufacturers that combine reliable radiation delivery with strong imaging, planning software, service support, and clinical training may be better positioned to address the needs of expanding cancer care networks.”
• Strategic Implications
  • Equipment manufacturers should demonstrate how imaging, treatment planning, and radiation delivery work together, while clearly identifying regulatory clearances and the indications supported by each system.
  • Hospitals and cancer centers need to assess treatment throughput, staffing requirements, service availability, installation costs, and the ability to integrate equipment into existing oncology workflows.
  • Healthcare policymakers must consider geographic access, referral pathways, workforce availability, and long-term maintenance when investing in radiotherapy infrastructure.
  • Radiation oncology teams can select treatment approaches according to clinical evidence, tumour location, patient needs, and the capabilities of the installed system.

Germany is set to record a 7.8% CAGR through 2036. Brazil is projected to post 7.1%, followed by the USA at 6.5%. The UK is estimated to advance at 5.8%, while Japan is forecast to grow at 5.1%.

Fact.MR finds that Linear Accelerators lead Product Type at 42.3%; Prostate Cancer leads Application at 24.5%; and Hospitals Lead End-User at 52.7%

Which Product Type dominates?

Linear Accelerators are set to hold 42.3% share in 2026.

Source: Fact.MR analysis. Updated Oct 29, 2026

Linear accelerators deliver high-energy radiation for conventional and advanced cancer treatments, including IMRT and image-guided radiotherapy. Hospitals assess imaging quality and maintenance support when selecting systems. Proton therapy may reduce exposure to surrounding tissues, while specialized stereotactic platforms serve distinct clinical applications.

What leads the Application segment?

Prostate Cancer is set to represent 24.5% share in 2026.

Source: Fact.MR analysis. Updated Oct 29, 2026

Prostate cancer is an important application for radiation oncology because external beam treatment can be incorporated into care plans according to disease stage, tumour characteristics, and patient circumstances. The choice of radiation technique depends on clinical assessment rather than equipment availability alone. Breast cancer, lung cancer, head and neck cancer, and other indications also contribute to demand. These applications require different planning approaches, positioning procedures, dose schedules, and methods for limiting exposure to healthy tissue. Manufacturers therefore compete on treatment precision and clinical support.

How does End-User shape demand?

Hospitals are likely to account for 52.7% share in 2026.

Source: Fact.MR analysis. Updated Oct 29, 2026

Hospitals often coordinate radiation oncology with diagnostic imaging, pathology, surgery, medical oncology, and follow-up services. These links can support the treatment of patients whose care requires input from multiple specialties. Larger hospitals may also have the patient volume and clinical infrastructure needed to operate sophisticated radiotherapy equipment. Ambulatory Radiotherapy Centers can attract demand by offering specialized outpatient treatment and dedicated radiation oncology services. Cancer Research Institutes may purchase advanced systems for clinical research, treatment evaluation, and specialized programmes.

Government initiatives to expand cancer care infrastructure and improve access to radiotherapy support demand for external beam radiation therapy systems. However, high equipment costs and the need for trained professionals can limit adoption, particularly in healthcare facilities with constrained budgets. Ongoing maintenance expenses may further influence purchasing decisions.

Drivers Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Opportunity Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Restraints Impact Analysis

Source: Fact.MR analysis. Updated Oct 29, 2026

Source: Fact.MR analysis. Updated Oct 29, 2026

What supports Germany adoption?

7.8% CAGR, supported by ongoing cancer care needs and investment in advanced treatment capabilities.

Germany's aging population and continuing demand for cancer treatment support the need for modern oncology services. Destatis reported in February 2026 that approximately 230,400 people died from cancer in Germany in 2024 and that around 1.45 million hospital treatment cases involved cancer that year [6].

Hospitals may consider replacing aging systems with equipment that improves imaging, treatment precision, and operational efficiency. Investment decisions will also depend on reimbursement, clinical staffing, and the ability to integrate new technology into established cancer treatment pathways.

How is Brazil developing external beam radiation therapy adoption?

7.1% CAGR, driven by efforts to expand radiotherapy access and address regional differences in treatment capacity.

Brazil's National Cancer Institute (INCA) estimated 781,000 new cancer cases annually for 2026–2028, including approximately 518,000 cases annually when non-melanoma skin cancers are excluded. The institute highlighted persistent regional inequalities in access to prevention, early diagnosis, and timely treatment [7].

Brazil's Ministry of Health also reported in October 2026 that new linear accelerators were being installed to improve access to radiotherapy through the public health system. These investments may support equipment procurement and training needs as treatment capacity expands.

What supports United States adoption?

6.5% CAGR, led by a large cancer care system and continued development of advanced radiation treatment technologies.

The U.S. National Cancer Institute reported in September 2026 that the latest Annual Report to the Nation found an increase in overall cancer incidence from 2018 to 2022, driven in part by rising breast and prostate cancer incidence. [8]

Technology development also supports demand for equipment upgrades. In September 2026, Siemens Healthineers announced Accela, a radiotherapy solution designed around its NeoArc treatment delivery approach. The announcement highlighted faster stereotactic treatment workflows and advanced imaging and planning capabilities. Its stated regulatory status should be considered before interpreting the launch as evidence of unrestricted commercial availability.

How is the United Kingdom building adoption?

5.8% CAGR, shaped by investment in cancer services and efforts to improve treatment capacity.

The UK government announced in May 2025 that £70 million would support the rollout of modern linear accelerator machines at 28 hospitals, with the aim of helping more patients receive treatment faster. [9]

In February 2026, the Department of Health and Social Care and NHS England published the National Cancer Plan for England, setting out a strategy to improve cancer care and outcomes through 2035. [10]

What supports Japan adoption?

5.1% CAGR, backed by established proton therapy expertise and continued development of specialized cancer treatment facilities.

Japan has an established base of advanced radiotherapy services, including proton beam therapy. In July 2025, Hitachi High-Tech announced that it had received an order for a proton therapy system for Komagome Hospital in Tokyo, with operations scheduled to begin in fiscal year 2030. The planned facility includes an accelerator and two rotating gantry treatment rooms [11] .

In September 2025, Hitachi High-Tech and project partners announced the start of treatment using a renewed proton therapy system at the University of Tsukuba Hospital[12]. These projects illustrate continued investment in specialized treatment infrastructure. Adoption will also depend on clinical suitability, capital requirements, treatment capacity, and long-term operational support.

Fact.MR identifies Siemens Healthineers AG (Varian), Elekta AB, Accuray Incorporated, Ion Beam Applications S.A. (IBA), and Hitachi High-Tech Corporation as the five companies to profile across the external beam radiation therapy equipment and technology landscape.

Elekta received U.S. FDA 510(k) clearance for its Elekta Evo CT-Linac in January 2026. In September 2026, the company also announced expanded adaptive radiotherapy capabilities across its portfolio, including CT-guided and MR-guided treatments and radiosurgery [13]. Accuray Incorporated and RaySearch Laboratories company announced an expanded collaboration in September 2026 to integrate RayStation treatment-planning software with Accuray platforms. The initial focus is on Radixact, with plans to extend the solution to CyberKnife. The agreement is intended to support online adaptive radiation therapy workflows [14]. IBA and Penn Medicine announced the formation of Noventra Oncology Alliance on September 28, 2026. The joint venture is intended to help healthcare providers develop and operate proton therapy and advanced radiation oncology programmes, including strategic planning, clinical readiness, and long-term operational support [15].  

Key companies include Siemens Healthineers AG (Varian), Elekta AB, Accuray Incorporated, Ion Beam Applications S.A. (IBA), and Hitachi High-Tech Corporation

• Siemens Healthineers AG (Varian)
• Elekta AB
• Accuray Incorporated
• Ion Beam Applications S.A. (IBA)
• Hitachi High-Tech Corporation

• [1] National Cancer Institute. (2025, May 15). External beam radiation therapy for cancer.
• [2] Ministry of Defence, Government of India. (2026, May 25). Army Hospital (R&R) commissions modern radiotherapy technology for advanced cancer care. Press Information Bureau.
• [3a] Ministério da Saúde. (2026, October 14). Roraima inicia atendimentos de radioterapia com primeiro acelerador linear do SUS no estado.
• [3b] Ministério da Saúde. (2026, October 17). Santos (SP) passa a contar com dois aceleradores lineares para tratar pacientes com câncer.
• [4] Siemens Healthineers. (2026, September 27). The future of radiotherapy is here: Siemens Healthineers launches Accela.
• [5] Elekta. (2026, September 27). Elekta expands adaptive workflows across its radiotherapy portfolio.
• [6] Statistisches Bundesamt (Destatis). (2026, February 2). Sterblichkeit aufgrund von Krebs geht in nahezu allen Altersgruppen zurück.
• [7] Instituto Nacional de Câncer. (2026, September 14). INCA estima 781 mil novos casos de câncer por ano no Brasil entre 2026 e 2028.
• [8] National Cancer Institute. (2026, September 22). Annual Report to the Nation on the Status of Cancer.
• [9] Department of Health and Social Care, & NHS England. (2025, May 26). Faster cancer treatment thanks to new radiotherapy machines.
• [10] Department of Health and Social Care, & NHS England. (2026, February 4). National Cancer Plan for England.
• [11] Hitachi High-Tech Corporation. (2025, July 2). New proton therapy facility to be established at Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital – Scheduled to begin operations in fiscal year 2030.
• [12] Hitachi High-Tech Corporation. (2025, September 30). The second proton therapy system begins treatment at University of Tsukuba Hospital.
• [13] Elekta. (2026, January 16). Elekta receives FDA 510(k) clearance for Elekta Evo linear accelerator.
• [14] Accuray Incorporated. (2026, September 11). Accuray and RaySearch agree to collaboration integrating RayStation software with Accuray platforms to accelerate Accuray's online adaptive capabilities.
• [15] IBA. (2026, September 28). Penn Medicine and IBA launch joint venture to advance proton therapy and radiation oncology program development worldwide.

• The report examines the market for external beam radiation therapy equipment and its use across the cancer applications.
• Product analysis compares linear accelerators, proton therapy systems, CyberKnife, Gamma Knife, and other platforms.
• Application analysis covers prostate cancer, breast cancer, lung cancer, head and neck cancer, and other indications.
• Country analysis discusses Germany, Brazil, the USA, the UK, and Japan alongside available official healthcare statistics and infrastructure developments.
• The competitive overview profiles Siemens Healthineers AG (Varian), Elekta AB, Accuray Incorporated, Ion Beam Applications S.A. (IBA), and Hitachi High-Tech Corporation
• The report reviews recent product developments, regulatory clearances, collaborations, and equipment investments relevant to radiotherapy adoption.

The market covers equipment and associated technologies that deliver therapeutic radiation from an external source to a defined area of the body. It includes conventional linear accelerators and specialized platforms used for stereotactic and proton-based treatment. Demand is influenced by cancer treatment requirements, equipment replacement cycles, clinical capabilities, healthcare funding, and the availability of trained radiation oncology professionals.

What is included in the scope?

Included products comprise linear accelerators, proton therapy systems, CyberKnife, Gamma Knife, and other qualifying external radiation platforms. The application scope includes prostate cancer, breast cancer, lung cancer, head and neck cancer, and other cancer indications. End-user coverage includes hospitals, cancer research institutes, and ambulatory radiotherapy centers, together with other relevant providers.

What is excluded from the scope?

The analysis excludes brachytherapy equipment used solely to deliver radiation from sources placed inside or next to the treatment area, diagnostic imaging systems that do not deliver therapeutic radiation, and pharmaceutical cancer treatments. General hospital equipment and unrelated oncology services are also excluded unless specifically included in the defined external beam radiation therapy product boundary.

How Was the Analysis Built?

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews.

• Primary Research: Primary research includes discussions with manufacturers, service providers, technology developers, distributors, end users, and subject-matter experts. These conversations examine purchasing priorities, product adoption, operational challenges, approval requirements, competitive positioning, and the factors that influence wider market acceptance.
• Desk Research: Desk research covers government statistics, regulatory publications, company filings, trade data, technical studies, industry associations, standards, public policy, and other authoritative sources. Every source used in the analysis is documented in the bibliography.
• Market Sizing and Forecasting: Market estimates combine historical performance, demand indicators, pricing and volume trends, segment shares, company participation, country-level growth, adoption patterns, investment activity, and barriers to market expansion.
• Data Validation and Update Cycle: Findings are validated by comparing primary interviews with public data, company activity, regulatory changes, trade patterns, and industry developments. Regular updates review new product launches, capacity changes, partnerships, approvals, and shifts in commercial adoption.